問卷

TPIDB > Principal Investigator

Principal Investigator


MacKay Memorial Hospital (在職)

Division of Obstetrics & Gynecology

Division of Obstetrics & Gynecology

MacKay Memorial Hospital

Division of Obstetrics & Gynecology

更新時間:2023-09-19

陳子健
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

26Cases

2020-05-01 - 2025-12-31

Phase II

Completed
A Phase II, Safety, and Efficacy Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Patients With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer
  • Condition/Disease

    Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer

  • Test Drug

    Tiragolumab/TECENTRIQ (Atezolizumab)

Participate Sites
5Sites

Recruiting5Sites

2021-07-01 - 2025-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2020-03-01 - 2027-12-31

Phase III

Active
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18/ENGOT-cx11/GOG-3047)
  • Condition/Disease

    Uterine Cervical Neoplasms

  • Test Drug

    Pembrolizumab (MK-3475)Pembrolizumab (MK-3475)

Participate Sites
3Sites

Recruiting3Sites

2019-02-01 - 2026-11-30

Phase III

Active
xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
8Sites

Recruiting8Sites

2021-12-16 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting3Sites

Terminated2Sites

2018-06-11 - 2023-01-31

Phase III

Completed
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer
  • Condition/Disease

    Advanced Endometrial Cancer

  • Test Drug

    Keytruda/Lenvima

Participate Sites
7Sites

Terminated7Sites

王鵬惠
Taipei Veterans General Hospital

Division of Obstetrics & Gynecology

2022-05-01 - 2025-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-03-01 - 2025-03-31

Phase III

Not yet recruiting
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18/ENGOT-cx11/GOG-3047)
  • Condition/Disease

    Locally Advanced Cervical Cancer

  • Test Drug

    Pembrolizumab (MK-3475) Pembrolizumab (MK-3475)

Participate Sites
3Sites

Recruiting3Sites

2021-05-21 - 2024-06-30

Phase III

Completed
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
  • Condition/Disease

    Cervical Cancer

  • Test Drug

    Tisotumab Vedotin

Participate Sites
3Sites

Recruiting1Sites

Terminated2Sites

2011-06-01 - 2018-02-28

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

1 2 3